This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Nivolumab for platinum-resistant advanced or recurrent ovarian cancer

< Back

Nivolumab for platinum-resistant advanced or recurrent ovarian cancer


Cancer and Palliative Care

October 2019

Nivolumab is in development for the treatment of platinum-resistant, advanced or recurrent ovarian cancer. Ovarian cancer is one of the most common types of cancer in women. The symptoms of the disease are vague, including loss of appetite and tummy pain. This can mean that the cancer is often diagnosed when the disease is advanced and more difficult to treat. Most patients have the cancer removed by surgery and also receive chemotherapy, which usually includes platinum-based drugs. However, ovarian cancer often recurs and the platinum-based chemotherapy drugs may be less effective at treating this recurrence. If the cancer recurs within 6 months of the previous treatment, and platinum-based chemotherapy does not work, the disease is called ‘platinum resistant’.
Nivolumab works by improving the activity of white blood cells increasing the ability of the immune system to kill cancer cells. Currently patients with platinum resistant or recurrent ovarian cancer have few treatment options and if licensed, nivolumab could be an effective treatment option.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts